Eliran Elimelech, Startup Nation Central VP of Ecosystem Development: Most of the companies are in AI and pharma. "Since 7.10, we have seen the Israeli high-tech industry still delivering the goods" Eliran Elimelech, VP of Ecosystem Development at Startup Nation Central (SNC) declared, speaking at the at the Novartis Healthcare Innovation Conference, and emphasizing the position of the local biomed companies.
"Since the beginning of the war, $2.5 billion has been raised in 176 funding rounds, and mergers and acquisitions worth $3.5 billion have been carried out, of which 39 were in the healthcare sector, as compared with 32 in cyber, and 36 in enterprise and IT.
" RELATED ARTICLES The exec who decides which drugs Novartis will develop The scout who learned to look for the quiet ones "We seek star researchers, pioneers in their fields" "We want to be a bridge between Israel and the world" True, SNC summary data for the first quarter show that the figure for the absolute amounts invested in Israeli privately-held life science companies was the weakest since data gathering commenced in 2018, but the numbers indicate that there is activity in this sector as well. Elimelech noted that there were currently 1,600 life science companies in Israel, comprising 20% of the high-tech sector. In 2023, he says, $7 billion was raised from funds and companies for investment in healthcare tech companies, or $8 billion if public companies are included.
"The most significant funding rounds were f.